BRIEF published on 10/29/2025 at 18:35, 1 month 6 days ago Theraclion Announces 2025 Half-Year Financial Results and Strategic Progress Financial Results Revenue Growth Market Expansion U.S. Study Certification Progress
PRESS RELEASE published on 10/29/2025 at 18:30, 1 month 6 days ago Inside Information / News release on accounts, results Theraclion reports successful pivotal study, CE certification, GB 9706.1-2020 certification; 89% revenue increase and 23% operating loss reduction in 2025 half-year results Revenue Increase Operating Loss Reduction CE Certification Pivotal Study Theraclion
BRIEF published on 10/21/2025 at 18:35, 1 month 14 days ago Theraclion obtains crucial certification in China Medical Theraclion SONOVEIN® Focused Ultrasound Chinese Certification
BRIEF published on 10/10/2025 at 18:35, 1 month 25 days ago Monthly publication of Theraclion voting rights Share Capital Voting Rights Investment Euronext Growth Theraclion
PRESS RELEASE published on 10/10/2025 at 18:30, 1 month 25 days ago Inside Information / Other news releases Theraclion provides monthly update on total voting rights and shares. The French MedTech company uses focused ultrasound for non-invasive treatment. CE-marked platform SONOVEIN® targets varicose veins Voting Rights Shares Theraclion SONOVEIN Focused Ultrasound
BRIEF published on 09/15/2025 at 18:35, 2 months 19 days ago Theraclion Successfully Completes Pivotal Study with 96.8% Occlusion Rate FDA Clinical Trial Theraclion SONOVEIN® Varicose Veins
PRESS RELEASE published on 09/15/2025 at 18:30, 2 months 19 days ago Inside Information / Other news releases Theraclion announces successful U.S. FDA pivotal study showing 96.8% occlusion rate with Sonovein® for varicose vein treatment. Results support potential U.S. market entry Theraclion SONOVEIN® U.S. FDA Study Varicose Vein Treatment Occlusion Rate
BRIEF published on 07/25/2025 at 18:35, 4 months 10 days ago Theraclion in full expansion in the first half of 2025 Financial Results Clinical Trials Business Expansion Theraclion SONOVEIN
PRESS RELEASE published on 07/25/2025 at 18:30, 4 months 10 days ago Inside Information / News release on accounts, results Theraclion reports strong growth in S1 2025 with increased revenue and expansion into new markets. Key achievements include 30% rise in consumables sales and completion of pivotal FDA clinical trial follow-up period Revenue Growth Business Expansion Theraclion FDA Clinical Trial S1 2025
BRIEF published on 07/09/2025 at 18:35, 4 months 26 days ago Review of the first half of 2025 of the Theraclion liquidity contract Liquidity Contract Half-yearly Report Euronext Growth Theraclion Securities Traded
Published on 12/05/2025 at 02:35, 2 hours 47 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 22 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 17 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 22 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 52 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 32 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 57 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 7 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 12 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 22 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 37 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 38 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 21 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
